Controlled trial of antilymphocyte globulin in cadaveric transplantation.
Since January 1974, alternate cadaveric renal transplants were treated with antilymphocyte globulin (Behringwerke) om addotopm to prednisone and azathioprine. Thirty patients were treated in this way. 53% of patients receiving ALG had a functioning graft at six months as opposed to 40% in the control group. This difference is not significant. All other parameters were approximately equal in the two groups. No serious side effects of ALG treatment were observed.
D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D002102:Cadaver; D002986:Clinical Trials as Topic; D006085:Graft Survival; D006801:Humans; D016030:Kidney Transplantation; D008231:Lymphopenia / Q000139:chemically induced; D014181:Transplantation Immunology
D000961:Antilymphocyte Serum